NasdaqCM - Delayed Quote USD
Eupraxia Pharmaceuticals Inc. (EPRX)
At close: November 6 at 4:00 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
31,849.5830
27,847.2290
17,617.4520
14,648.9286
1,761.4989
Operating Income
-31,849.5830
-27,847.2290
-17,617.4520
-14,648.9286
-1,761.4989
Net Non Operating Interest Income Expense
5.3490
-307.2040
-551.0570
-965.4437
-1,475.2706
Other Income Expense
4,156.3540
-775.1500
-822.2550
-2,714.3998
91.5658
Pretax Income
-27,687.8800
-28,929.5830
-18,990.7640
-18,328.7721
-3,145.2037
Tax Provision
36.4230
36.4230
--
--
--
Net Income Common Stockholders
-26,998.5950
-28,220.7960
-18,489.6290
-18,030.7807
-3,134.6670
Diluted NI Available to Com Stockholders
-26,998.5950
-28,220.7960
-18,489.6290
-18,030.7807
-3,134.6670
Basic EPS
-0.93
-1.17
-0.96
-1.47
-0.24
Diluted EPS
-0.93
-1.17
-0.96
-1.47
-0.24
Basic Average Shares
29,326.6730
24,146.6230
19,285.4470
12,405.8380
12,865.2730
Diluted Average Shares
29,326.6730
24,146.6230
19,285.4470
12,405.8380
12,865.2730
Rent Expense Supplemental
--
--
--
--
30.9255
Total Expenses
31,849.5830
27,847.2290
17,617.4520
14,648.9286
1,761.4989
Net Income from Continuing & Discontinued Operation
-26,998.5950
-28,220.7960
-18,489.6290
-18,030.7807
-3,134.6670
Normalized Income
-30,531.4959
-27,755.7060
-17,667.3740
-17,089.2762
-3,226.2328
Interest Income
1,185.2600
862.9690
431.7990
51.5506
0.3349
Interest Expense
1,179.9110
1,170.1730
982.8560
1,016.9942
1,475.6054
Net Interest Income
5.3490
-307.2040
-551.0570
-965.4437
-1,475.2706
EBIT
-26,507.9690
-27,759.4100
-18,007.9080
-17,311.7779
-1,669.5983
EBITDA
-26,348.5720
-27,603.8830
-17,860.0140
-17,224.3055
-1,577.9949
Reconciled Depreciation
159.3970
155.5270
147.8940
87.4724
91.6034
Net Income from Continuing Operation Net Minority Interest
-26,998.5950
-28,220.7960
-18,489.6290
-18,030.7807
-3,134.6670
Total Unusual Items Excluding Goodwill
4,156.3540
-775.1500
-822.2550
-941.5044
91.5658
Total Unusual Items
4,156.3540
-775.1500
-822.2550
-941.5044
91.5658
Normalized EBITDA
-30,504.9260
-26,828.7330
-17,037.7590
-16,282.8011
-1,669.5607
Tax Rate for Calcs
0.0002
0.0004
--
--
--
Tax Effect of Unusual Items
623.4531
-310.0600
--
--
--
12/31/2020 - 4/5/2024
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
IBO Impact BioMedical Inc.
2.5990
-3.74%
FRES Fresh2 Group Limited
1.3864
-15.98%
TSBX Turnstone Biologics Corp.
0.5700
+19.85%
AVTE Aerovate Therapeutics, Inc.
2.7600
+2.22%
EDSA Edesa Biotech, Inc.
2.7400
+3.40%
PHGE BiomX Inc.
0.7800
+1.30%
NGENF NervGen Pharma Corp.
1.8000
+1.69%
SABS SAB Biotherapeutics, Inc.
3.9500
-4.59%
ZNTL Zentalis Pharmaceuticals, Inc.
3.8400
+1.59%
ACOG.CN Alpha Cognition Inc.
10.00
-16.67%